What do you really know about Medicaid? Take our quiz and find out.
What do you really know about Medicaid? Take our quiz and find out.
Medicaid will be at the center of talks this week on Capitol Hill as House Republicans consider how to cut a program that is the primary source of health insurance coverage for low-income populations. Paid for by the federal government and states (as well as D.C.), Medicaid is a lifeline for many groups, including children and seniors.
Members of the Energy and Commerce Committee, which has jurisdiction over health care, are charged with finding $880 billion in savings, which they can't do without touching Medicaid. Yet some lawmakers say they won't vote for a bill that scales back a program on which many of their constituents rely.
How much do you know about how Medicaid works? Test your knowledge with our quiz:
Story continues below advertisement
Advertisement
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Local leaders respond to potential Medicaid cuts
DERBY, Conn. (WTNH) — Leaders of multiple local hospitals came together Monday morning to warn what might happen if Republicans in Congress pass their proposed changes to Medicaid. They worry state and local costs will skyrocket if the federal government makes proposed changes to how the program works. One of the proposed changes involves charging low-income patients a co-pay of as much as $35 for certain medical appointments. Hartford HealthCare introduces 'Empowering New Parents' program 'What this does is act as a barrier,' said Griffin Hospital CEO Patrick Charmel. 'People will see they have an out-of-pocket responsibility and just won't pursue the care that they need.' Eventually, he said, those people will end up in the emergency room, which ends up costing more. The Trump administration contends their changes will lower insurance premiums, but Congresswoman Rosa DeLauro (D-CT3) disagrees. 'Premiums for individual plans sold on Access Health CT will increase by as much as 25% next year,' DeLauro said. DeLauro says proposed cuts threaten access to health care for nearly 14 million people nationwide. A white house spokesman had a different take in an emailed statement. 'President Trump pledged to protect and preserve Medicaid, and that's exactly what The One, Big, Beautiful accomplishes by kicking illegal immigrants off the program, implementing commonsense work requirements, and enforcing basic eligibility verification to combat fraud,' wrote spokesman Kush Desai. Hartford HealthCare and Pfizer partner to tackle workplace migraines For those not on Medicaid, they may wonder why they should care about these cuts. Hospitals have to provide care to everybody who needs it, whether they can pay for it or not. If there is less money from the government coming in to pay for low-income patients, that means hospitals that are already stretched thin financially, could find themselves in serious financial trouble. 'Cuts to programs that support our communities like Medicaid will stress that ecosystem further and bring changes, challenges and collapses to some of our critical infrastructure across the state of Connecticut,' said Dr. Tom Balcezak, EVP & Chief Clinical Officer, Yale New Haven Health System. Which, they say, means fewer people seeing fewer doctors. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Medscape
24 minutes ago
- Medscape
ASCO 2025: Key Updates in Early Breast Cancer Care
Mariana Chavez MacGregor, MD, MSc, comments on how the ASCO 2025 meeting delivered a wealth of impactful data, particularly in the early-stage breast cancer setting. Trials like neoCARHP and CompassHER2 raised important questions about de-escalating therapy for HER2-positive patients, challenging the role of carboplatin and demonstrating strong pathologic complete response rates with shorter regimens. Long-term data from SOFT and TEXT reinforced the survival benefits of ovarian suppression plus an aromatase inhibitor in high-risk premenopausal patients, and the OASIS 4 study showed promise with elinzanetant in managing vasomotor symptoms. Across subtypes, including triple-negative disease, and with the growing role of AI and circulating tumor DNA, the meeting emphasized more personalized, less toxic approaches to care.
Medscape
24 minutes ago
- Medscape
ASCO 2025: Key Highlights in Advanced Lung Cancer
Just returned from ASCO 2025, Isabel Preeshagul, DO, comments on intriguing data that were presented, including results from REZILIENT1, which showed a 35% response rate for zipalertinib in patients with epidermal growth factor receptor exon 20-altered stage IV non-small cell lung cancer (NSCLC), even those previously treated with targeted therapies, with manageable toxicity. An unexpected finding from another study in the advanced NSCLC space suggested that administering immunochemotherapy before 3:00 PM was associated with better outcomes, possibly due to circadian influences on immune response. In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and exertional shortness of breath. Finally, Dr Preeshagul notes how the IMforte study reported promising results for maintenance atezolizumab plus lurbinectedin, with improved progression-free survival and overall survival, making it a potential option pending further risk-benefit discussion.
